# **Product** Data Sheet

## Cinnamic acid-d<sub>6</sub>

Storage:

Cat. No.: HY-N0610AS CAS No.: 91453-04-2 Molecular Formula:  $C_9H_2D_6O_2$ Molecular Weight: 154.2

Target: **Endogenous Metabolite** Pathway: Metabolic Enzyme/Protease

-20°C Powder 3 years 2 years

-80°C In solvent 6 months

-20°C 1 month

#### **SOLVENT & SOLUBILITY**

DMSO: 250 mg/mL (1621.27 mM; Need ultrasonic) In Vitro

DMSO: 250 mg/mL (1621.27 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	6.4851 mL	32.4254 mL	64.8508 mL
	5 mM	1.2970 mL	6.4851 mL	12.9702 mL
	10 mM	0.6485 mL	3.2425 mL	6.4851 mL

Please refer to the solubility information to select the appropriate solvent.

### **BIOLOGICAL ACTIVITY**

Description  $Cinnamic\ acid-d_{6}\ is\ the\ deuterium\ labeled\ Cinnamic\ acid\ has\ potential\ use\ in\ cancer\ intervention,\ with\ IC50s$ of 1-4.5 mM in glioblastoma, melanoma, prostate and lung carcinoma cells.

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to

affect the pharmacokinetic and metabolic profiles of drugs<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

#### **REFERENCES**

In Vitro

[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.

2]. Liu L, et al. Cinnamic acid: a	natural product with potentia	l use in cancer intervention. Int	: J Cancer. 1995 Jul 28;62(3):345-50.	
			dical applications. For research use	
	Tel: 609-228-6898 Address: 1 D	Fax: 609-228-5909 eer Park Dr, Suite Q, Monmo	E-mail: tech@MedChemExpressouth Junction, NJ 08852, USA	s.com

Page 2 of 2 www.MedChemExpress.com